Si deseas distinguir tus productos, servicios o ambos de los de otra empresa, es posible que necesites una marca o nombre comercial. Descubre qué son, en qué consiste su procedimiento de registro y qué implica.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Si tienes un nuevo dispositivo, producto o procedimiento que resuelva un problema técnico o tenga una ventaja práctica, existen distintas formas de protegerlo en España y en otros países. Descubre cómo hacerlo.
¿Tu innovación reside en la estética, la ornamentación o la apariencia de tu producto? Protégela mediante un diseño industrial. Descubre qué derechos confiere el registro y cómo realizar la tramitación.
Las indicaciones geográficas protegen el nombre de un producto originario de una zona geográfica, a la cual le debe una determinada calidad, reputación u otra característica. Descubre qué son, en qué consiste su procedimiento de registro y qué beneficios conceden.
Las patentes publicadas en todo el mundo son una valiosa fuente de información científica, técnica y comercial.
Si eres emprendedor/a o una empresa y quieres potenciar y mejorar la rentabilidad de tu negocio protegiendo de forma adecuada los activos intangibles de tu organización, en este espacio encontrarás lo necesario.
87
resultados
Última actualización
11/05/2026 [06:45:00]
Resumen de: US20260125367A1
0000 Disclosed are compounds, methods, compositions, and kits that allow for treating cancer by, e.g., targeting cancer stem cells. In some embodiments, the cancer is colorectal cancer, gastric cancer, gastrointestinal stromal tumor, ovarian cancer, lung cancer, breast cancer, pancreatic cancer, prostate cancer, testicular cancer, or lymphoma. In some embodiments, the cancer is liver cancer, endometrial cancer, leukemia, or multiple myeloma. The compounds utilized in the disclosure are of Formula (0), (O′), and (I):
0000
Resumen de: US20260124190A1
0000 Disclosed herein are embodiments of a method for treating a disease or condition in a subject, comprising administering to the subject, a pyrazole compound according to formula I.
0000
0000 The compound may be administered as a composition, such as a spray-dried formulation. The disease or condition may be hidradenitis suppurativa, or a lymphoid neoplasm, and may be chronic myeloid leukemia or chronic myelomonocytic leukemia.
Resumen de: US20260125387A1
The present invention relates to (R)—N-ethyl-5-fluoro-N-isopropyl-2-(5-(2-(6-((2-methoxyethyl)(methyl)amino)-2-methylhexan-3-yl)-2,6-diazaspiro3.4octan-6-yl)-1,2,4-triazin-6-yl)oxy)benzamide besylate salt and solvates thereof.This compound may be useful for therapy and/or prophylaxis in a mammal, pharmaceutical composition comprising such compound, and use as menin/MLL protein/protein interaction inhibitor, useful for treating diseases such as cancer, including but not limited to leukemia, myelodysplastic syndrome (MDS), and myeloproliferative neoplasms (MPN); and diabetes.
Resumen de: US20260124222A1
The invention provides isothiazolylcarboxamide compounds, pharmaceutical compositions, their use for inhibiting mucosa-associated lymphoid tissue lymphoma translocation protein 1 (MALT 1), and their use in the treatment of a disease or condition, such as a proliferative disorder, inflammatory disorder, or autoimmune disorder.
Resumen de: US20260125654A1
The present invention relates to the method for producing a three-dimensional (3D) model of multiple myeloma (MM), in the form of spheroids, by co-culturing mesenchymal stem/stromal cells, endothelial progenitors and primary plasma cells of patient(s) affected by MM. The present invention further relates to the spheroids obtained by said method and the uses thereof.
Resumen de: US20260124273A1
Disclosed is a method of using Netrin-1 (NTN1) driven rejuvenation of an aged hematopoietic system based on its shown dependency of reestablishing integrity of aged bone marrow niche and reactivating DNA damage response (DDR). NTN1 is shown as a master regulator of reactivating DNA damage response (DDR) pathways. Every organ/tissue accumulates DNA damage that is an underlying cause of diseases. Reactivating DDR has an extensive effect on treating diseases. NTN1 serves as a therapeutic modality that effectively reverses age-related hematopoietic deficiencies while simultaneously targeting growth and survival of acute myelogenous leukemia (AML). The ability to target and gene correct hematopoietic stem cells (HSC) ex vivo for the treatment of hemoglobinopathies, like thalassemia and sickle cell anemia, is limited due to inability of transducing the correct cell population. NTN1 is shown to maintain and expand bona fide HSCs, opening up the possibility to transduce a true stem cell overcoming previous limitations.
Resumen de: US20260125645A1
The present application relates to methods for expanding hematopoietic stem cells (HSC) and/or hematopoietic progenitor cells (HPC) ex vivo and/or in vivo. The methods comprise culturing the HSCs and/or HPCs in the presence of a selective 5-Hydroxytryptamine Receptor 1F (HTR1F) agonist and/or of a Thyroid Hormone Receptor Beta (THRB) agonist, and/or in an air-liquid interface (ALI) culture system. The expanded HSCs and/or HPCs, which maintain engraftment and immune reconstitution properties, may be administered to subjects suffering from various diseases including cancer, immunodeficiencies, myelodysplastic syndrome (MDS) or anemia. The present application also relates to the use of HTR1F and/or THRB agonists for stimulating HSC and/or HPC expansion, and for increasing the number of immune cells or for reconstituting the immune system, in vivo.
Resumen de: US20260124242A1
0000 Methods of expanding peripheral blood lymphocytes (PBLs) from blood of patients with hematological malignancies, including lymphomas and leukemias, genetic modifications of expanded PBLs to incorporate chimeric antigen receptors, genetically modified T cell receptors, and other genetic modifications, and uses of such expanded and/or modified PBLs in the treatment of diseases such as cancers and hematological malignancies are disclosed herein.
Resumen de: US20260125436A1
This disclosure relates to methods and compositions for treating cancer including advanced solid tumor, a metastatic solid tumor or lymphoma using an inducible IL-12 prodrug.
Resumen de: WO2026096487A1
The present disclosure provides methods of treating acute myeloid leukemia by administering an effective amount of a DNMT1 inhibitor, or a pharmaceutically acceptable salt thereof, and an USP48 inhibitor, or a pharmaceutically acceptable salt thereof.
Resumen de: WO2026096787A1
Provided herein are, inter alia, methods and compositions for the treatment of leukemia. The methods include administering to a subject AOH1996 or a combination of AOH1996 and a Bcl-2 inhibitor. Administration of a combined synergistic amount of the AOH1996 and the Bcl-2 inhibitor results in a surprisingly increased anti-leukemia efficacy.
Resumen de: WO2026097044A1
A composition comprising a complex containing a polynucleotide of interest and a carrier is provided. The surface of the complex is coated covalently or non-covalently with a CD22 receptor ligand and can target CD22 on cells. The carrier may contain a polymer, a lipid, or a protein. The polynucleotide of interest may contain, for example, plasmid DNA (pDNA), linear double stranded DNA (dsDNA), linear single stranded DNA (ssDNA), messenger RNA (mRNA), small hairpin RNA (shRNA), or small interfering RNA (siRNA) that alters level or activity of a target molecule in B cells. Methods of delivering a polynucleotide of interest to a CD22 expressing cell, and methods of treating a B cell-associated disease (such as acute lymphoblastic leukemia) in a subject using the composition are also provided.
Resumen de: WO2026096597A1
The present disclosure provides multispecific anti-CD22/anti-4-1BB antigen-binding molecules comprising a first antigen-binding domain that binds specifically to CD22 and a second antigen-binding domain that binds specifically to 4-1 BB. In certain embodiments, the molecules further comprise a third antigen-binding domain that binds 4-1 BB. In certain embodiments, the molecules are multispecific antibodies or antigen-binding fragments thereof. In certain embodiments, the antibodies are useful in treating a CD22-associated disease or disorder (e.g., lymphoma).
Resumen de: WO2026093435A1
Immunotherapy leverages the body's immune system to target cancer cells, but some tumors resist this treatment due to low infiltration of T CD8+ cells and high infiltration of regulatory T cells in the tumor microenvironment. The inventors showed that a JAK inhibitor (i.e. ruxolitinib) reshapes the tumor immune microenvironment resulting in T regulatory cells reduction and T CD8+ cells increase. Ruxolitinib-mediated immune microenvironment effects create new therapeutic opportunities by enhancing anti-PD1 treatment efficacy in cSCC and melanoma and other immunotherapy resistant cancer types such as pancreatic cancer and acute myeloid leukemia (AML). Cell-based immunotherapy response is also improved in AML. Accordingly, the present invention relates to the use of JAK inhibitors for enhancing the potency of immunotherapy.
Resumen de: WO2026097062A1
Disclosed are methods of monitoring minimum residual disease using genomic profiling. In some methods, a subject has or has had multiple myeloma or a precursor thereof. The methods include amplifying a sample using primary template-directed whole genome amplification (PTWGA) and enable monitoring of liquid samples, such as blood samples.
Resumen de: WO2026093987A1
The present invention is directed biphenyl derivatives, pharmaceutical compositions containing said compounds, and the use of said compounds in the treatment of leukemias, lymphomas and other cancers.
Resumen de: US20260124300A1
0000 The present invention relates to methods of treating B-cell lymphomas, e.g., primary refractory or relapsed diffuse large B-cell lymphoma (DLBCL), by administering an anti-CD20/anti-CD3 bispecific antibody (e.g., glofitamab) and in combination with one or more anti-CD20 antibodies (e.g., obinutuzumab and/or rituximab) and one or more chemotherapeutic agents selected from ifosfamide, carboplatin, and/or etoposide.
Resumen de: WO2026095708A1
The present invention relates to a pharmaceutical composition for preventing or treating cancer, the pharmaceutical composition containing CD4+ CTL as an active ingredient. The CD4+ CTL according to the present invention performs a cytotoxic function of directly attacking and killing myeloma cells, thereby extending the progression-free survival of transplant-ineligible myeloma patients, and thus can contribute to increasing the survival rate of the patients. In addition, by using NKG2D+ CD4+ CTL as a biomarker for predicting the prognosis of myeloma patients, it is possible to analyze the CD4+ CTL status of individual patients and thereby establish customized treatment strategies. In addition, by increasing the cytotoxicity of NKG2D+ CD4+ CTL through a specific cytokine treatment, it is possible to more effectively prevent or treat cancer.
Resumen de: US20260125449A1
0000 Provided are adoptive cell therapy methods involving the administration of doses of cells for treating disease and conditions, including certain B cell malignancies. The cells generally express recombinant receptors such as chimeric antigen receptors (CARs). In some embodiments, the methods are for treating subjects with non-Hodgkin lymphoma (NHL). In some embodiments, the methods are for treating subjects with relapsed or refractory NHL. Also provided are articles of manufacture and prophylactic treatments in connection with adoptive therapy methods.
Resumen de: WO2026094004A2
Provided herein are methods and compositions for treating multiple myeloma, such as relapsed and/or refractory multiple myeloma and newly-diagnosed multiple myeloma, including transplant-ineligible newly-diagnosed multiple myeloma (TI-NDMM). The methods involve administering to human patients diagnosed with multiple myeloma an anti-BCMA antigen binding protein (e.g., an anti-BCMA antibody or anti-BCMA antibody drug conjugate) in combination with lenalidomide, pomalidomide, bortezomib, carfilzomib and/or dexamethasone.
Resumen de: WO2026093986A1
The present invention is directed biphenyl derivatives, pharmaceutical compositions containing said compounds, and the use of said compounds in the treatment of leukemias, lymphomas and other cancers.
Resumen de: WO2026094019A1
The present disclosure relates to computer-implemented methods for classifying cell neighborhoods in a bone marrow sample obtained from a subject suffering from multiple myeloma (MM) and for defining significant cell neighborhoods in that sample that are associated with treatment outcomes in subjects with MM who receive a T cell-redirecting therapy. Image processing systems that can be used to analyze bone marrow samples and identify cell neighborhoods are also provided. Moreover, methods for predicting a treatment response to a T cell-redirecting therapy in a subject suffering from MM are disclosed.
Resumen de: WO2026095315A1
The present invention relates to a novel compound having inhibitory activity against leukemia cell lines and a medical use thereof. The novel compound according to the present invention has excellent inhibitory activity against leukemia cell lines and thus can treat related diseases, and in particular, has an excellent therapeutic effect on acute myeloid leukemia (AML) and thus can be effectively used for treating leukemia as described above.
Resumen de: WO2026096908A1
The present disclosure provides, inter alia, methods and compositions for the treatment of a cancer such as, e.g., a lymphoma, in a subject in need thereof. Also provided are methods for treating or ameliorating the effects of hypoxia in the tumor microenvironment (TME) in a subject having a cancer.
Nº publicación: EP4736887A2 06/05/2026
Solicitante:
AUTOLUS LTD [GB]
Autolus Limited
Resumen de: EP4736887A2
0001 The present invention relates to a chimeric antigen receptor (CAR) which comprises an antigen-binding domain which selectively binds TCR beta constant region 1 (TRBC1) or TRBC2; cells; such a T cells comprising such a CAR; and the use of such cells for the treatment of a T-cell lymphoma or leukaemia in a subject.
BOPI
Sede Electrónica
